key: cord-0314896-e2lckzox
authors: Mueller, Katherine P.; Piscopo, Nicole J.; Forsberg, Matthew H.; Saraspe, Louise A.; Das, Amritava; Russell, Brittany; Smerchansky, Madeline; Shi, Lei; Ali, Adeela; Lazzarotto, Cicera R.; Tsai, Shengdar Q.; Capitini, Christian M.; Saha, Krishanu
title: CRISPR-mediated insertion of a chimeric antigen receptor produces nonviral T cell products capable of inducing solid tumor regression
date: 2021-08-08
journal: bioRxiv
DOI: 10.1101/2021.08.06.455489
sha: e6715c2e5eac71ff1f34c8db85f87a0b12318017
doc_id: 314896
cord_uid: e2lckzox

Chimeric antigen receptor (CAR) T cells traditionally harbor viral vectors that encode the CAR transgene in the genome. However, viral vector manufacturing typically is resource intensive, suffers from batch-to-batch variability, and includes several animal components, adding regulatory and supply chain pressures. Here, CAR T cells were generated within nine days using recombinant SpCas9 protein and nucleic acids, without any viral vectors or animal components. In comparison to traditional retroviral CAR T cells, nonviral CRISPR CAR T cells exhibit TRAC-targeted genomic integration of the CAR transgene, higher frequency of gene expression signatures associated with a memory phenotype, low receptor signaling prior to infusion, and potent cytotoxicity against GD2+ neuroblastoma in vitro and in vivo. This proof-of-principle study eliminating viral vectors and animal components during CAR gene transfer could enable more flexible and scalable manufacturing of clinically-relevant, high-quality CAR T cells to treat cancers, including solid tumors.

Schematic showing the CAR genetic construct and nonviral strategy to insert the CAR into the first exon of the human TRAC locus. The seed sequence of the gRNA is in blue and the protospacer adjacent motif (PAM) for SpCas9 is underlined. LHA: left homology arm, 14g2a: single chain variable fragment clone targeting GD2; SA: splice acceptor, 2A: self-cleaving peptide, pA: rabbit ß-globin polyA terminator. Arrows indicate positions of primers for In-Out PCR assay shown in Fig. 2 . b, Summary of manufacturing schedule and analyses for all cell products. RV-CAR, donormatched CAR T cell product generated by retroviral transduction with the same third generation anti-GD2 CAR shown in a; NV-mCh, donor-matched control T cell product manufactured nonvirally as in a but with an mCherry fluorescent protein instead of the CAR. c, Representative density flow cytometry plots for transgene and TCR surface protein levels on the manufactured cell products. Y-axis shows CAR or mCherry levels and x-axis shows TCR levels on day 7 post isolation (day 5 post-electroporation for NV-CAR and NV-mCh, and day 4 post-transfection for control RV-CAR). Thick black-lined boxes delineate cell populations selected for downstream analysis. Histograms show CAR expression for the three test groups. Boxplots show the percentage of CAR positive cells in each sample, and mean fluorescence intensity (MFI) values for the CAR expression levels, respectively. d, Histograms show TCR expression on the three test groups. Boxplots show the percentage of CAR positive cells in each sample. * indicates p<=0.05; ** indicates p<=0.01; *** indicates p<=0.001; **** indicates p<=0.0001.

After confirming robust CAR protein expression, we next performed genomic analysis to measure the on-target specificity of the gene edit. Proper genomic integration of the CAR was confirmed via an "in-out" PCR amplification assay 33 on the genomic DNA extracted from the manufactured cell products with primers specific to the TRAC locus and the transgene (Fig. 2a, Extended Data Fig.   1c ). Next-generation sequencing of genomic DNA to profile any TRAC alleles in the cell products without an integrated transgene confirmed high rates of genomic disruption at the TRAC locus for these residual alleles, with 93.06% indels for the NV-CAR and NV-mCh samples. Altogether, the combined genomic integration of the CAR or mCherry transgene and indels at the TRAC locus resulted in concomitant loss of TCR protein of the T cell surface in sample-matched assays (Fig   2b, c) . Genome-wide, off-target analysis for our editing strategy was assayed by CHANGE-seq 34 .

The top modified genomic site was identified to be the intended on-target site (Fig. 2d, e) with a Text with Figures, Page 8 rapid drop-off for off-target modifications elsewhere in the genome.The CHANGE-seq specificity ratio of our TRAC editing strategy is above average (0.056; 57 th percentile) when compared to published editing strategies previously profiled by CHANGE-seq 34 . Fig. 1a by arrows upstream of the LHA and within the CD28 sequence of the CAR. Untransf., untransfected donor-matched T cells; NTC, non-template control. b, Percent of cells with indels at the TRAC locus in both NV-CAR and NV-mCh conditions. NV-CAR (blue) N=10; NV-mCh (grey) N=8, both for one donor. c, Level of TCR editing in NV-CAR and NV-mCh T cells measured by both flow cytometry (left) and deep sequencing of genomic DNA (presence of insertions and deletions, indels, at the TRAC locus, right). NV-CAR (blue) N=10, NV-mCh (grey) N=8. d, Manhattan plot of CHANGE-seq-detected on-and off-target sites organized by chromosomal position with bar heights representing CHANGE-seq read count. The on-target site is indicated with the blue arrow. e, Visualization of sites detected by CHANGE-seq. The intended target sequence is shown in the top line. Cleaved sites (on-and off-target) are shown below and are ordered top to bottom by CHANGE-seq read count, with mismatches to the intended target sequence indicated by colored nucleotides. Insertions are shown in smaller lettering between genomic positions, deletions are shown by (-). Output is truncated to top sites.

Cytokine profiling reveals high antigen-specific response for NV-CAR T cells. After harvesting CAR T cells, we profiled secreted cytokines typically associated with a proinflammatory response. On day 9 of manufacturing prior to antigen exposure, RV-CAR T cells produced higher levels of IFN, TNF, IL-2, IL-4, IL-10, IL-13, IL-6, IL-1 and IL-12p70, in comparison to both NV-CAR and NV-mCh T cells (Fig. 3a) . To test the possibility that RV-CAR T cells produced higher amounts of cytokines regardless of antigen exposure, we performed a 24 hour co-culture between the engineered T cells and GD2+ CHLA20 neuroblastoma, then measured cytokines from the conditioned media. Interestingly, we found that in the presence of antigen stimulation, the previous trend had reversed: NV-CAR T cells either matched or surpassed the level of cytokine production of the RV-CAR T cells (Fig. 3a) . This result suggests that cytokine production after a single antigen stimulation is comparable in NV-CAR and RV-CAR T cells, regardless of their initial behavior at harvest.

To test the possibility that variation in cytokine production prior to cognate antigen exposure resulted from varying levels of baseline signaling from the CAR and/or TCR during ex vivo expansion, we assayed CD3 phosphorylation from both native CD3 and the CD3 portion of the CAR via western blot (Fig. 3b) . We found elevated protein levels of both CAR and TCRassociated CD3 in RV-CAR T cells relative to NV-CAR T cells, potentially indicative of both   Text with Figures, Page 10 high CAR copy number in RV products and an intact TCR-CD3 complex in the absence of TRAC knockout. We also observed higher levels of CD3 phosphorylation in RV-CAR T cells from both CAR and TCR-associated protein, indicating elevated levels of basal signaling. In the absence of antigen exposure, this suggests the presence of tonic signaling, a phenotype that has been associated with an increased propensity for terminal differentiation and exhaustion in some CAR T cell products [35] [36] [37] . NV-CAR and NV-mCherry cells both showed sharply decreased TCRmediated CD3 signaling after TRAC knockout, and NV-CAR T cells also showed very little activity from CAR-associated CD3. This is consistent with prior findings that TCR replacement with a CD19 CAR can decrease CAR-mediated tonic signaling by driving expression by the native TRAC promoter 16 . Values are pooled from all four donors. NV-CAR (blue) N=24; RV-CAR (green) N=33; NV-mCherry (gray) N=22. a (right), Cytokine production in conditioned media after a 24 hour coculture of manufactured T cell products with the target GD2-antigen on CHLA20 neuroblastoma cells. Values are pooled from two donors. NV-CAR (blue) N=8; RV-CAR (green) N=5; NV-mCh (gray) N=8. The minimum and maximum for the color scale for each cytokine is as follows: IFNy, 2000-30000 pg/mL. TNF-a, 10-1000 pg/mL. IL-2, 700-6000 pg/mL. IL-4, 0.2-20 pg/mL. IL-10, 0.5-150 pg/mL. IL-13, 300-1100 pg/mL. IL-8, 25-1800 pg/mL. IL-6, 10-400 pg/mL. IL-p70, 0.1-4 pg/mL. IL-1b, 0.2-100 pg/mL. b, Western blot from cell lysates featuring 40% transgene+ cells and stained for CD3z, pCD3z, and GAPDH. Native CD3z and GD2.28.40.z. CD3z domains were distinguished by molecular weight (15 and 60 kDa, respectively). N=1 donor.

To further define the phenotypic differences between NV-CAR, NV-mCh, and RV-CAR T cells, we performed single-cell RNA-sequencing (scRNA-seq) on 79,317 cells from two different donors, both at the end of the manufacturing process and after 24 hours of coculture with GD2+ CHLA20 neuroblastoma cells (Fig. 4a) . We observed no significant donorspecific or batch effects, as indicated by gross clustering patterns in the combined data set.

Further, we observed no significant changes in transcript levels for genes at or within 5 kb of offtarget sites predicted by CHANGE-seq, indicating that any potential genomic disruptions at these sites did not lead to detectable changes in proximal transcripts. To distinguish edited transgenepositive and transgene-negative cells within each sample, we aligned reads to a custom reference genome containing an added sequence mapping to the CAR or mCherry transgenes. Subsequent transcriptional analyses were carried out on transgene-positive cells only within each sample (21,068 cells total). We performed tSNE dimensionality reduction and clustering on all cells and identified clusters with gene expression patterns associated with various phenotypes, including memorylike and effector-like populations across CD4 and CD8 subsets (Fig. 4a) . We examined the distribution of transgene+ cells within each cluster, and found that prior to antigen stimulation, Text with Figures, Page 13 55% of NV-CAR and 61% of NV-mCherry T cells fell into clusters with a memory-like phenotype, while only 25% of RV-CAR T cells did so; conversely, 49% of RV-CAR T cells at harvest had effector-like phenotypes, while 33% of NV-CAR T cells and 27% of NV-mCherry T cells fell into these clusters (Fig. 4b) . This suggests that prior to cognate antigen exposure, TRAC knockout plays a role in memory formation and maintenance of a less differentiated phenotype, as measured at the transcriptional level. This finding was corroborated by elevated CD62L protein expression in both NV-CAR and NV-mCh cells relative to RV-CAR cells, as measured by flow cytometry (Fig 4c) . The mean fluorescence intensity (MFI) of CD62L increased by approximately three-fold in the NV-CAR T cells relative to the RV-CAR T cells. Increased CD62L is consistent with TRAC-CAR T cells featuring a CD19 CAR 16 , and may indicate elevated memory formation after manufacturing, although additional protein-level data are needed to confirm this hypothesis (Fig. 4c) .

Notably, we observed that the skew toward a memory-like phenotype at the transcriptional level did not persist for NV-CAR or RV-CAR T cells after cognate antigen exposure. After 24 hours of co-culture with GD2+ neuroblastoma cells in vitro, the distribution of transgene+ cells within each cluster shifted such that 27% of NV-CAR and 21% of RV-CAR T cells expressed memory-associated transcriptional signatures, while 60% of NV-mCherry cells expressed this phenotype; conversely, 53% and 59% of NV-CAR and RV-CAR T cells expressed effector-like transcriptional signatures after coculture, while only 24% of NV-mCherry cells did so. This indicates that both NV and RV CAR T cells can mount a robust effector response, while NV-mCherry cells lacking either a CAR or TCR retain their lessdifferentiated phenotype when exposed to cancer.

Text with Figures, Page 14 CHLA20 neuroblastoma and M21 melanoma (Fig. 5a) . We performed both a fluorescence-based cytotoxicity assay, measuring loss of expression from fluorescently labeled cancer cells over time (Fig 5b) , and IncuCyte live cell analysis at 2-hour intervals over a 48 hour period (Fig. 5c) .

We observed potent killing using a 5:1 effector:target ratio for both NV-CAR and RV-CAR T cells, using both assays. These results corroborate our finding that NV-CAR T cells produce proinflammatory cytokines and upregulate a cytotoxicity-associated gene signature at levels comparable to RV-CAR T cells, and demonstrate potent target cell killing for multiple GD2+ cancers of variable origin. compared to isotype controls (gray). b, Graphs show the cytotoxic action of NV-CAR and RV-CAR T cells against two GD2-positive tumor cell lines, CHLA20 and M21, containing a stably integrated fluorescent transgene (AkaLuc-GFP and H2B-mCherry, respectively). Cytotoxicity was measured by change number of mCherry-positive objects for each image. The assay was performed using cells manufactured from one donor. c, IncuCyte in vitro assay of T cell potency, averaged across four donors. AnnexinV was added as a marker of cell death; y-axis shows GFPpositive cancer cells in each well of a 96-well plate. The ratio of T cells to cancer cells is 5:1. The consistent decrease in CHLA20 cells after 15 hours indicates high potency of both NV-CAR and RV-CAR T cells. NV-CAR (blue) N=12; RV-CAR (green) N=12; CHLA20 neuroblastoma alone (black) N=9. *indicates p<=0.05; ** indicates p<=0.01; *** indicates p<=0.001; **** indicates p<=0.0001.

Finally, we assessed CAR T cell potency in vivo in an established human GD2+ neuroblastoma xenograft model. After 9 total days of culture, multiple replicate wells of RV-CAR, NV-CAR, or NV-mCh T cells were pooled for injection into NOD-SCID-c -/-(NSG) mice (Jackson Laboratory).

Ten million T cells were delivered via tail vein injection to each NSG mouse with an established luciferase-expressing CHLA20 neuroblastoma tumor identified by bioluminescence (Fig. 6a) . Fig. 2c) . Additionally, we observed that cells in the spleen had lower levels of PD-1, LAG-3 and TIM-3 exhaustion markers after NV-CAR treatment relative to the RV-CAR treatment in lymphocytes recovered from the spleen ( Fig. 6e-g, Extended Data Fig. 2d ). These findings demonstrate comparable potency of NV-CAR T cells to standard RV-CAR T cells, establishing the potential clinical relevance of NV-CAR T cells for treating solid tumors.

a, Schematic of the in vivo mouse dosing strategy using NSG mice harboring GD2-positive CHLA20 neuroblastoma tumors. b, Representative IVIS images of NSG mice with CHLA20 tumors that were treated with either 10 million NV-CAR, RV-CAR, or NV-mCh T cells. c, Kaplan-Meyer survival curve for mice. NV-CAR (blue) N=10; RV-CAR (green) N=8; NV-mCh (gray) N=7. d, Box plots show presence of CAR+CD45+ human T cells in mouse spleens, as measured by flow cytometry. e, Flow cytometry plots showing levels of PD-1 and LAG-3 on the human lymphocytes (CD45+) cells collected from mouse spleens. f, Flow cytometry plots show human CD45+CAR+ NV-CAR and RV-CAR T cells are found in tumors, but NV-mCh cells are not. g, Flow cytometry plots showing levels of PD-1 on human CD45+ lymphocytes collected from mouse tumors.

Historically, CAR T cells have exhibited frustratingly limited success against solid tumors.

While anti-GD2 CAR T cells were the first to mediate regression of a solid tumor 38 in patients, the effects ultimately were not durable due in part to poor T cell persistence 26 . The third generation CAR used in this study failed to mediate meaningful anti-tumor responses in patients when delivered as a retroviral construct 39 ; therefore, we sought to determine whether a TRAC-CAR replacement strategy, previously shown to be successful in the context of a CD19 CAR, could improve outcomes. Extensive work has focused on overcoming the immunosuppressive tumor microenvironment; however, there is an urgent need for new engineering strategies to make the cell product itself more potent, whether through armored CARs, T cell selection procedures, combinatorial therapies. or other approaches [40] [41] [42] . Leveraging prior work on hematological malignancies where anti-CD19 AAV-CAR T cells were manufactured using AAV and SpyCas9 16 , we develop a completely nonviral workflow that can accommodate a large CAR template (~3kb) targeting a solid tumor antigen, GD2. Our findings open new avenues for manufacturing highquality and defined genome-edited, NV-CAR T cells to treat solid tumors.

Here we describe reproducible, nine-day manufacturing of third generation GD2-specific CAR T cells using recombinant SpCas9 protein and nucleic acids. Our manufacturing process produced similar yields across four donors and resulted in stable, genomically-integrated, durable CAR expression (>80 days in vivo) without the use of any viral vectors or animal-derived components during gene transfer or scale up. The decrease in T cell viability linked to nucleofection 43 is transient in our workflow with cells recovering to >80% viability just one week after nucleofection, satisfying typical regulatory thresholds. Our use of high-density culture to improve T cell aggregation may stimulate pro-survival cell-cell signaling to overcome stress arising from nucleofection. Furthermore, cell proliferation is likely to have an added benefit, as homologous recombination is active in the S and G2 phases of the cell cycle and increases in HDR have been observed in cycling cells 44 . We also improve the ease of manufacturing the HDR repair template by performing two sequential Solid Phase Reversible Immobilization-based purification steps on the PCR products. This purification procedure concentrates the template and is facile, keeping preparation time and cost-per-reaction low. Further, we do not rely on excipients to increase editing efficiency, which have been proposed recently 45 , and thereby provide a streamlined gene transfer process. Altogether, these methodological changes constitute an important advance for the adoptive T cell therapy in enabling clinically relevant, rapid, and efficient nonviral CAR T cell manufacturing.

In retroviral CAR T products, vector copy numbers can vary, 46, 47 and genomic integration is scattered across >10,000 sites in the human genome 3 . The CAR expression in retroviral products therefore can be affected by both the copy number and various chromatin contexts of each vector integrant across the various cells in a product. In contrast, our strategy inserts the CAR at a single site (TRAC) at a copy number of 1 or 2, where the CAR transgene is driven by only one promoter, the endogenous TRAC promoter. CRISPR strategies with AAV donor templates integrate, at 5-20% frequencies, the entire AAV vector into the Cas9-induced DNA double strand break 48 and therefore may disrupt TRAC regulation. Hence, variable CAR expression within a cell product can depend on the degree of AAV vector integration. Thus, usage of a virus-free CRISPR strategy can reduce variability in CAR expression (Fig. 1c) . Undesired genomic alterations and adverse events arising from genome editing are low: the on-target specificity of our editor is above average when compared to many other editing strategies 34 , with no detectable transcriptional changes in genes at or proximal to predicted off-target sites in the edited cells. Our strategy to use SpCas9 as RNPs versus encoded on mRNAs 16 Immobilization (SPRI) cleanup (1X) using AMPure XP beads according to the manufacturer's instructions (Beckman Coulter). Each 100 µl starting product was eluted into 5 µl of water. Bead incubation and separation times were increased to 5 minutes, and elution time was increased to 15 minutes at 37°C to improve yield. PCR products from round 1 cleanup were pooled and subjected to a second round of SPRI cleanup (1X) to increase total concentration; round 2 elution volume was 20% of round 1 input volume. Template concentration and purity was quantified using NanoDrop 2000 and Qubit dsDNA BR Assays (Thermo Fisher Scientific), and templates were diluted in water to an exact concentration of 2 µg/µl. Recombinant sNLS-SpCas9-sNLS Cas9 (Aldevron, 10 mg/ml, total 0.8 µl) was added to the complexed gRNA at a 1:1 molar ratio and incubated for 15 minutes at 37°C to form an RNP.

Individual aliquots of RNPs were incubated for at least 30 seconds at room temperature with HDR templates for each sample prior to electroporation. ~50 million cells per replicate were aliquoted per reaction. RNPs were complexed as described above, but with 40 µl Cas9 per reaction (50X scale). During the RNP complexation step, T cell aliquots were centrifuged for 10 min at 90g. During the spin step, 100 µl HDR template (total 200 µg) per condition were aliquoted to 1.5 mL tubes, followed by RNPs (140 µl per well). Templates and RNPs were incubated at room temperature for at least 30 seconds. After cell centrifugation, supernatants were aspirated, and cells were resuspended in 750 µl P3 buffer (Lonza), then transferred to 1.5 mL tubes containing RNP, bringing the total volume per sample to ~1 mL (pellet is assumed to be ~10 µl). Each sample was transferred directly to a 1 mL Nucleocuvette Cartridge (Lonza). T cells were electroporated with a Lonza 4D Nucleofector with LV Unit using pulse code EH115. Immediately after nucleofection, the cartridge was transferred to an incubator to rest at 50 mM HEPES buffered DMEM + 10% FBS (Gibco). 48 hours later, media was collected, stored at 4°C, and replaced. A second aliquot of media was collected 24 hours later; media aliquots were pooled and centrifuged for 10 min at 2000g to pellet contaminating cells, and supernatants were transferred to a clean conical tube. 1/3 volume Retro-X concentrator (Takara) was added, and supernatants were refrigerated at 4°C for 12-18 hours, then concentrated according to the manufacturer's instructions. Viruses were tested on 3T3 cells prior to use; yields from one 15 cm dish were used for 5 replicate wells of 160,000 T cells per transduction. Viruses were either used immediately for T cell spinoculation or stored at -80°C in single use aliquots. Next Generation Sequencing of genomic DNA. Indel formation at the TRAC locus was measured using Next Generation Sequencing (Illumina). Genomic PCR was performed according to the manufacturer's instructions using Q5 Hot Start polymerase (NEB); primers are listed in Supplementary Table 6 . Products were purified using SPRI cleanup with AMPure XP beads (Beckman Coulter), and sequencing indices were added with a second round of PCR using indexing primers (Illumina), followed by a second SPRI cleanup. Samples were pooled and sequenced on an Illumina MiniSeq according to the manufacturer's instructions. Analysis was performed using CRISPR RGEN (rgenome.net).

Genome-wide, off-target analysis. Genomic DNA from human primary CD4 + /CD8 + T cells was isolated using Gentra Puregene Kit (Qiagen) according to the manufacturer's instructions.

CHANGE-seq was performed as previously described 23 hours. The change in protocol was made due to institutional COVID-19 biosafety precautions.

Single cell RNA sequencing. 24 hours prior to assay, 200,000 AkaLUC-CHLA20 cells were plated in 12 well plates and cultured overnight. One week after electroporation (day 9 postisolation), T cells were counted and pooled into a single bank for characterization studies (scRNAseq, IncuCyte cytotoxicity assay and in vivo experiments). Media was aspirated from cancer cells, and 1 million T cells in ImmunoCult-XF Medium + 500 U/mL IL-2 were seeded on the cancer cells, then cultured for 24 hours. A parallel T cell-only single culture (termed "pre-antigen") was set up at the same density in a separate 12 well plate. The next day, co-culture cells were trypsinized for donor 1 and washed off the plate with media, and cells were singularized with a 35

Text with Figures, Page 35 µM cell strainer (Corning). For donor 2, co-culture cells were stained for CD45 and CAR, and FACS sorted into CD45 + CAR + and CD45 + CARfractions prior to sample submission. Cells were counted with a Countess II FL cell counter using trypan blue exclusion (Thermo Fisher Scientific), and samples were prepared for single cell RNA sequencing with the 10X Genomics 3' kit (v3 chemistry) according to the manufacturer's instructions. Libraries were sequenced using the Illumina NovaSeq 6000 system. FASTQ files were aligned with Cellranger v3.0.1 to custom reference genomes that included added sequences for the transgene(s) used in each culture condition (e.g., the TRAC NV-CAR donor sequence, mCherry donor sequence, etc.). Downstream analyses were performed using Seurat 3. In brief, each dataset was filtered to include only cells with 200 or more unique genes, and genes expressed in three or more cells. Data were normalized and scaled, and mitochondrial mapping percentage was regressed out as a confounding source of variation. Datasets were then integrated, and dimensionality reduction was performed with Principal Components Analysis. Cells were clustered based on their genome-wide transcriptional profiles using t-distributed stochastic neighbor embedding (tSNE), and differential gene expression was calculated using Seurat 3. Clusters were For each sample, cells expressing the transgene of interest (CAR or mCherry) were identified, and transgene-negative cells were removed from the dataset. All analysis scripts will be deposited in the Saha Lab GitHub repository upon publication. System (IVIS), and 10 million T cells were injected through the tail vein into each mouse. Mice were followed for weight loss and overall survival. On imaging days, mice were sedated using isoflurane and received intraperitoneal injections of ~120 mg/kg D-luciferin (GoldBio). Fifteen minutes later, mice were imaged via IVIS. Imaging was repeated every 3 to 4 days, starting 1 day before initial T cell injection (Day -1). Mice were injected with 100,000 IU of human IL-2 subcutaneously on day 0, day 4, and with each subsequent IVIS reading. In order to quantify the total flux in the IVIS images, a region of interest (ROI) was drawn around the bottom half of each mouse with the total flux being calculated by Living Image® software (PerkinElmer; Total flux = the radiance (photons/sec) in each pixel summed or integrated over the ROI area (cm 2 ) x 4π). The absolute minimum total flux value was subtracted from each image to minimize background signal. For donors 1, 3, and 4, mice were maintained until tumors reached 20mm in any dimension by digital caliper as defined by the ACUC.

For donor 2, all mice were euthanized on day 25. Tumors and spleens were removed, mechanically dissociated, and passed through a Corning® 35µm cell strainer. Cell suspensions were centrifuged at 300g for 10 minutes, and then digested with ACK lysing buffer (Lonza). The cells were then washed and centrifuged at 300g for 10 minutes, and then resuspended in 10 ml PBS, 10 µl of which was added to 10 ml of ISOTON® diluent and counted on the COULTER COUNTER® Z1 Series Particle Counter (Beckman Coulter). From this count, 1x10 6 cells were added to flow cytometry tubes in staining buffer (PBS with 2% FBS) and stained with antibodies for hCD45, mCD45, scFV 14G2a CAR, and PD-1 (see Supplementary Table 5 

Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells

Chimeric antigen receptor T-cell therapy for solid tumors

The tumour glyco-code as a novel immune checkpoint for immunotherapy

Engineered T cells: the promise and challenges of cancer immunotherapy

Bioengineering Solutions for Manufacturing Challenges in CAR T Cells

Clinical manufacturing of CAR T cells: foundation of a promising therapy

CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration

Progress and challenges in viral vector manufacturing

Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors

Purification of mRNA Encoding Chimeric Antigen Receptor Is Critical for Generation of a Robust T-Cell Response

A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity

The road ahead in genetics and genomics

The promise and challenge of therapeutic genome editing

Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

Repurposing endogenous immune pathways to tailor and control chimeric antigen receptor T cell functionality

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults

Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15

Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma

Mechanisms of resistance to CAR T cell therapy

c-Jun overexpression in CAR T cells induces exhaustion resistance

Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma

High levels of AAV vector integration into CRISPR-induced DNA breaks

Reprogramming human T cell function and specificity with non-viral genome targeting

Fast, efficient and virus-free generation of TRAC-replaced CAR T cells

Pooled Knockin Targeting for Genome Engineering of Cellular Immunotherapies

Increasing the precision of gene editing in vitro, ex vivo, and in vivo

A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells

CRISPR-based gene editing enables FOXP3 gene repair in IPEX patient cells

CHANGE-seq reveals genetic and epigenetic effects on CRISPR-Cas9 genome-wide activity

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent

Strategies to Address Chimeric Antigen Receptor Tonic Signaling

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

CAR T cells administered in combination with lymphodepletion and PD-1 inhibition to patients with neuroblastoma

Engineering CAR-T Cells for Next-Generation Cancer Therapy

CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment

Teaching an old dog new tricks: next-generation CAR T cells

Critical testing and parameters for consideration when manufacturing and evaluating tumor-associated antigen-specific T cells

Controlled Cycling and Quiescence Enables Efficient HDR in Engraftment-Enriched Adult Hematopoietic Stem and Progenitor Cells

Polymer-stabilized Cas9 nanoparticles and modified repair templates increase genome editing efficiency

Optimized Assessment of qPCR-Based Vector Copy Numbers as a Safety Parameter for GMP-Grade CAR T Cells and Monitoring of Frequency in Patients

Application of droplet digital PCR for the detection of vector copy number in clinical CAR/TCR T cell products

Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy

Highly efficient multiplex human T cell engineering without doublestrand breaks using Cas9 base editors

One-step generation of modular CAR-T cells with AAV-Cpf1

A versatile system for rapid multiplex genome-edited CAR T cell generation

Controlling CRISPR with Small Molecule Regulation for Somatic Cell Genome Editing

Regeneration of CD8αβ T Cells from T-cell-Derived iPSC Imparts Potent Tumor Antigen-Specific Cytotoxicity

High Frequency Production of T Cell-Derived iPSC Clones Capable of Generating Potent Cytotoxic T Cells

Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy

Progenitor T-cell differentiation from hematopoietic stem cells using Deltalike-4 and VCAM-1

Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity

Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells

Global Transcriptional Response to CRISPR/Cas9-AAV6-Based Genome Editing in CD34+ Hematopoietic Stem and Progenitor Cells

Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory

Recent insights of T cell receptor-mediated signaling pathways for T cell activation and development

A multiscale simulation framework for the manufacturing facility and supply chain of autologous cell therapies

Text with Figures

Overcoming the Specific Toxicity of Large Plasmids Electrotransfer in Primary Cells In Vitro

Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell

Technologies and Computational Analysis Strategies for CRISPR Applications

A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells

Effects of cryopreservation on lymphocyte immunophenotype and function

Text with Figures

Extended Data Figure 1. Characterization of T cell products during manufacturing. a, Top left, Viability of cells throughout the manufacturing timeline, pooled for all 4 donors. Top right, Cell counts throughout the manufacture calendar

Bottom right, Cell counts throughout the manufacture calendar, using the 4D-Nucleofector LV unit for gene editing scaleup. N=1 for each reaction. b, Left, Percent of CAR+ cells as measured by flow cytometry when electroporated on day 2 or day 3 post-isolation. Right, Percent of TCR-cells as measured by flow cytometry when electroporated on day 2 or day 3 post-isolation. c, In-out PCR confirming NV-CAR insertion, full gel from Fig. 2a shown. PCR was optimized to minimize off-target amplification which occurs only for fragments <1 kb across the genome and does not vary by sample

NTC = non-template control. * indicates p<=0